Economic considerations on the usage of biologics in the allergy clinic.
allergy
asthma
biologics
cost utility
cost-effectiveness
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
28
01
2020
revised:
04
07
2020
accepted:
08
07
2020
pubmed:
14
7
2020
medline:
15
5
2021
entrez:
14
7
2020
Statut:
ppublish
Résumé
The advent of biologic therapies has transformed care for severe atopic disorders but their high cost poses new challenges with regard to long-term sustainability and fair allocation of resources. This article covers the basic concepts of cost-utility analyses and reviews the available literature on cost utility of biologic drugs in atopic disorders. When used within their limits as part of a multi-dimensional assessment, economic analyses can be extremely useful to guide decision-making and prioritization of care. Despite the good quality of most cost-utility analyses conducted for the use of biologics in asthma and other atopic diseases, their conclusions regarding cost-effectiveness are extremely variable. This is mainly due to the use of inconsistent estimates of health utility benefit with therapy. Development of reliable and validated instruments to measure disutility in atopic disorders and measure of indirect costs in atopic disease are identified as a priority for future research.
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
191-209Informations de copyright
© 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price!. BioDrugs. 2020;34(2):159-170.
Miller S. The $250 billion potential of biosimilars. 2013; http://lab.express-scripts.com/lab/insights/industry-updates/the-$250-billion-potential-of-biosimilars. Accessed July 29, 2019
Sanders GD, Maciejewski ML, Basu A. Overview of cost-effectiveness analysis. JAMA 2019;321(14):1400.
Neumann PJ, Sanders GD. Cost-effectiveness analysis 2.0. N Engl J Med 2017;376(3):203-205.
Kadom N, Itri JN, Trofimova A, Otero HJ, Horny M. Cost-effectiveness analysis: an overview of key concepts, recommendations, controversies, and pitfalls. Acad Radiol. 2019;26(4):534-541.
Guidelines for the economic evaluation of health technologies: Canada. 4th ed. Ottawa: CADTH; 2017.
Ashraf MA, Sherwani Y, Najim M, et al. Should basic health economics principles be taught during medical school in the UK? Med Educ Online. 2015;20:29541.
Beecroft C. Why health economics deserves a place in the medical curriculum. J Comp Eff Res. 2016;5(4):321-323.
Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 4th ed. Oxford, UK: Oxford University Press; 2014.
Henrikson NB, Skelly AC. Economic studies part I: basics and terms. Evid Based Spine Care J. 2012;3(4):7-11.
Angevine PD, Berven S. Health economic studies. Spine 2014;39:S9-S15.
Robinson R. Cost-utility analysis. BMJ 1993;307(6908):859-862.
Fanshel S, Bush JW. Health status index and its application to health services outcomes. Oper Res. 1970;18:1021-1066.
Fauteux V, Poder TG. État des lieux sur les méthodes d’élicitation du QALY. Int J Health Preference Res. 2017;1:2-14.
Mulhern B, Shah K, Janssen MF, Longworth L, Ibbotson R. Valuing health using time trade-off and discrete choice experiment methods: does dimension order impact on health state values? Value Health 2016;19(2):210-217.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5-21.
Richardson JRJ, Mckie JR, Bariola EJ. Multiattribute utility instruments and their use. In: Culyer AJ ed. Encylopedia of health economics, Volume 2. Vol 2. 1st ed. San Diego, CA: Elsevier; 2014:341-357.
Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316(10):1093-1103.
Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165-178.
Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness - the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371(9):796-797.
Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20(3):332-342.
Organization WH. Choosing interventions that are cost-effective. 2014; https://www.who.int/choice/en/. Accessed July 29, 2019
Fund IM. GPD per capita, current prices. 2019; https://www.imf.org/external/datamapper/NGDPDPC@WEO/OEMDC/ADVEC/WEOWORLD. Accessed July 29, 2019
ICER. Overview of the ICER value assessment framework and update for 2017-2019. Boston, MA: Institute for Clinical and Economic Review; 2017.
Poder TG. Challenges to make cost-effectiveness studies usable by decision makers. J Thorac Cardiovasc Surg. 2018;156(5):1931-1932.
Claxton K, Martin S, Soares M, et al. Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. Health Technol Assess. 2015;19(14):1-504.
Vernon JA, Goldberg R, Golec J. Economic evaluation and cost-effectiveness thresholds: signals to firms and implications for R & D investment and innovation. Pharmacoeconomics 2009;27(10):797-806.
Brock DW, Wikler D. Ethical issues in resource allocation, research, and new product development. In: Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, Jha P, Mills A, Musgrove P, eds. Disease control priorities in developing countries. Washington, DC: Oxford University Press; 2006.
Moon S, Mariat S, Kamae I, Pedersen HB. Defining the concept of fair pricing for medicines. BMJ 2020;368:l4726.
Komorowski M, Raffa J. Markov models and cost effectiveness analysis: applications in medical research. In MIT Critical Data eds. Secondary analysis of electronic health records. Cham, CH: Springer; 2016:351-367.
Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338.
Naimark D, Krahn MD, Naglie G, Redelmeier DA, Detsky AS. Primer on medical decision analysis: part 5-Working with Markov processes. Med Decis Making. 1997;17(2):152-159.
Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3(4):419-458.
Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: part 2-Building a tree. Med Decis Making. 1997;17(2):126-135.
van Haalen HG, Severens JL, Tran-Duy A, Boonen A. How to select the right cost-effectiveness model?: a systematic review and stepwise approach for selecting a transferable health economic evaluation model for rheumatoid arthritis. Pharmacoeconomics 2014;32(5):429-442.
Karnon J, Brown J. Selecting a decision model for economic evaluation: a case study and review. Health Care Manag Sci. 1998;1(2):133-140.
Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17(5):479-500.
Ofman JJ, Sullivan SD, Neumann PJ, et al. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003;9(1):53-61.
Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313(7052):275-283.
Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Br Med J. 2013;346:f1049.
Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J. 1998;12(6):1322-1326.
Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848-861.
Manka LA, Wechsler ME. Selecting the right biologic for your patients with severe asthma. Annals Allergy, Asthma Immunol. 2018;121(4):406-413.
IIfCaE. Biologic therapies for the treatment of asthma associates with type 2. (Review) September 24, 2018; 2018.
ICER. Biologic therapies for the treatment of asthma associates with type 2. Institute for Clinical and Economical Review; September 24, 2018; 2018.
Agache I, Akdis C, Akdis M, et al. EAACI biologicals guidelines - recommendations for severe asthma. Allergy 2021;76:14-44.
Brown R, Turk F, Dale P, Bousquet J. Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 2007;62(2):149-153.
Campbell JD, Spackman DE, Sullivan SD. The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective. Allergy 2010;65(9):1141-1148.
Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci. 2011;180(3):637-641.
Dal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol. 2011;43(2):45-53.
Dal Negro RW, Tognella S, Pradelli L. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy. J Asthma. 2012;49(8):843-848.
Dewilde S, Turk F, Tambour M, Sandstrom T. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden. Curr Med Res Opin. 2006;22(9):1765-1776.
Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value Health 2014;17(8):772-782.
Levy AN, Garcia ARAJ, Garcia-Agua Soler N, Sanjuan MV. Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective. J Asthma. 2015;52(2):205-210.
Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis. 2012;6(2):87-95.
Morishima T, Ikai H, Imanaka Y. Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in japan and the value of responder prediction methods based on a multinational trial. Value Health Reg Issues. 2013;2(1):29-36.
Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess. 2013;17(52):1-342.
Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol. 2004;114(2):265-269.
Suzuki C, Lopes da Silva N, Kumar P, Pathak P, Ong SH. Cost-effectiveness of omalizumab add-on to standard-of-care therapy in patients with uncontrolled severe allergic asthma in a Brazilian healthcare setting. J Med Econ. 2017;20(8):832-839.
Tadrous M, Khuu W, Lebovic G, et al. Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Ann Allergy Asthma Immunol. 2018;120(1):pp. 59-65 e52.
van Nooten F, Stern S, Braunstahl GJ, Thompson C, Groot M, Brown RE. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ. 2013;16(3):342-348.
Vennera Mdel C, Valero A, Uria E, Forne C, Picado C. Cost-effectiveness analysis of omalizumab for the treatment of severe persistent asthma in real clinical practice in Spain. Clin Drug Investig. 2016;36(7):567-578.
Wu AC, Paltiel AD, Kuntz KM, Weiss ST, Fuhlbrigge AL. Cost-effectiveness of omalizumab in adults with severe asthma: results from the Asthma Policy Model. J Allergy Clin Immunol. 2007;120(5):1146-1152.
Zafari Z, Sadatsafavi M, Mark FitzGerald J. Canadian respiratory research N. Cost-effectiveness of tiotropium versus omalizumab for uncontrolled allergic asthma in US. Cost Eff Resour Alloc. 2018;16:3.
Zafari Z, Fitzgerald M, Marra C, Sadatsafavi M. Cost-effectiveness of tiotropium versus omalizumab for patients with severe uncontrolled allergic asthma in us. Am J Respiratory Critical Care Med Conf. 2015;191:A3712 (MeetingAbstracts).
Zhou H, Lu Y, Wu B, Che D. Cost-effectiveness of omalizumab for the treatment of inadequately controlled severe allergic asthma in Chinese children. J Asthma. 2020;57(1):87-94.
McQueen RB, Sheehan DN, Whittington MD, van Boven JFM, Campbell JD. Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations. Pharmacoeconomics 2018;36(8):957-971.
Lam J, Hay JW, Salcedo J, Kenyon NJ. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2018;56(8):872-881.
Whittington MD, McQueen RB, Ollendorf DA, et al. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis. Ann Allergy Asthma Immunol. 2017;118(2):220-225.
Han S, Kim S, Kim H, Suh HS. Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting beta2-agonists in South Korea. Curr Med Res Opin. 2019;35(9):1597-1605.
Delong LK, Culler SD, Saini SS, Beck LA, Chen SC. Annual direct and indirect health care costs of chronic idiopathic urticaria: a cost analysis of 50 nonimmunosuppressed patients. Arch Dermatol. 2008;144(1):35-39.
Beltrani VS. An overview of chronic urticaria. Clin Rev Allergy Immunol 2002;23(2):147-169.
O'Donnell BF. Urticaria: impact on quality of life and economic cost. Immunol Allergy Clin North Am. 2014;34(1):89-104.
O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197-201.
Hawe E, McBride D, Balp MM, Tian H, Halliday A, Stull DE. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics 2016;34(5):521-527.
Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016;137(6):pp. 1742-1750 e1744.
Kaplan A, Ledford D, Ashby M, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132(1):101-109.
Maurer M, Rosén K, Hsieh H-J, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368(10):924-935.
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014;69(7):868-887.
Graham J, McBride D, Stull D, et al. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics 2016;34(8):815-827.
Kanters TA, Thio HB, Hakkaart L. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. Br J Dermatol. 2018;179(3):702-708.
Weller K, Maurer M, Grattan C, et al. ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. Clin Transl Allergy. 2015;5:29.
Holm JG, Agner T, Clausen ML, Thomsen SF. Quality of life and disease severity in patients with atopic dermatitis. J Eur Acad Dermatol Venereol. 2016;30(10):1760-1767.
Silverberg JI, Gelfand JM, Margolis DJ, et al. Health utility scores of atopic dermatitis in US adults. J Allergy Clin Immunol Pract. 2019;7(4):1246-1252.e1.
Cheng BT, Silverberg JI. Association between atopic dermatitis and lower health utility scores in US adults. Ann Allergy Asthma Immunol. 2020;124(1):88-89.
Drucker AM, Qureshi AA, Amand C, et al. Health care resource utilization and costs among adults with atopic dermatitis in the United States: a claims-based analysis. J Allergy Clin Immunol Pract. 2018;6(4):1342-1348.
Ariëns L, Gadkari A, Os-Medendorp H, et al. Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the eczema area and severity index. Acta Derm Venereol. 2019;99(10):851-857.
Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019;80(2):411-416.e4.
Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are biologics efficacious in atopic dermatitis? a systematic review and meta-analysis. Am J Clin Dermatol. 2018;19(2):145-165.
Simpson EL. Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials. Dermatol Ther (Heidelb). 2017;7(2):243-248.
Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090-1091.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130-139.
Kuznik A, Bégo-Le-Bagousse G, Eckert L, et al. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017;7(4):493-505.
Zimmermann M, Rind D, Chapman R, Kumar V, Kahn S, Carlson J. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drugs Dermatol. 2018;17(7):750-756.
ICER. Dupilumab and crisaborole for atopic dermatitis: effectiveness and valu. Boston, MA: Institute for Clinical and Economical Review;2017.
Ädelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2000;106(2):253-259.
Tajiri T, Matsumoto H, Hiraumi H, et al. Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol. 2013;110(5):387-388.
Gan EC, Habib AR, Rajwani A, Javer AR. Omalizumab therapy for refractory allergic fungal rhinosinusitis patients with moderate or severe asthma. Am J Otolaryngol. 2015;36(5):672-677.
Pauwels B, Jonstam K, Bachert C. Emerging biologics for the treatment of chronic rhinosinusitis. Expert Rev Clin Immunol. 2015;11(3):349-361.
Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology. 2010;48(3):318-324.
Gevaert P, Calus L, Van Zele T,, et al. Omalizumab is effective in allergic and non-allergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2012;129(2):AB69.
Penn R, Mikula S. The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol. 2007;21(4):428-432.
Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M. Efficacy of omalizumab in the treatment of nasal polyps. Thorax 2011;66(9):824-825.
Gevaert P, Calus L, Van Zele T, et al. Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol. 2013;131(1):110-116.e111.
Gevaert P, Van Bruaene N, Cattaert T, et al. Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis. J Allergy Clin Immunol. 2011;128(5):989-995.e8.
Bachert C, Sousa AR, Lund VJ, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140(4):1024-1031.e14.
Gevaert P, Langloidolt D, Lackner A, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118(5):1133-1141.
Bachert C, Mannent L, Naclerio RM, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA 2016;315(5):469-479.
Codispoti CD, Mahdavinia M. A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps. Ann Allergy Asthma Immunol 2019;123(3):232-239.
Pinto JM, Baroody FM, Naclerio RM. Uncharted waters: challenges in the era of biologic therapies for nasal polyposis. J Allergy Clin Immunol Pract. 2019;7(1):68-70.
Bégin P, Winterroth LC, Dominguez T, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy Asthma Clin Immunol. 2014;10(1):1.
Labrosse R, Graham F, Des Roches A, Begin P. The use of omalizumab in food oral immunotherapy. Arch Immunol Ther Exp (Warsz). 2017;65(3):189-199.
Martorell A, Alonso E, Echeverría L, et al. Oral immunotherapy for food allergy: a spanish guideline. Immunotherapy Egg and Milk Spanish Guide (ITEMS Guide). Part I: cow milk and egg oral immunotherapy: introduction, methodology, rationale, current state, indications, contraindications, and oral immunotherapy build-up phase. J Investig Allergol Clin Immunol. 2017;27(4):225-237.
Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT. A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol. 2013;132(6):1368-1374.
Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol. 2011;127(6):1622-1624.
Takahashi M, Soejima K, Taniuchi S, et al. Oral immunotherapy combined with omalizumab for high-risk cow's milk allergy: a randomized controlled trial. Sci Rep. 2017;7(1):17453.
Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy. J Allergy Clin Immunol. 2016;137(4):1103-1110.e11.
Leung DY, Shanahan WR Jr, Sampson HA. Response to "effect of anti-IgE therapy in patients with food allergy". Ann Allergy Asthma Immunol. 2003;91(6):515-517.
Sampson HA, Leung DYM, Burks AW, et al. A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127(5):1309-1310.e1.
Nilsson C, Nordvall L, Johansson SG, Nopp A. Successful management of severe cow's milk allergy with omalizumab treatment and CD-sens monitoring. Asia Pac Allergy. 2014;4(4):257-260.
Brandström J, Vetander M, Lilja G, et al. Individually dosed omalizumab: an effective treatment for severe peanut allergy. Clin Exp Allergy. 2017;47(4):540-550.
Hirano I, Dellon ES, Hamilton JD, et al. Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis. Gastroenterology 2020;158(1):111-122.e10.
Shaker M, Briggs A, Dbouk A, Dutille E, Oppenheimer J, Greenhawt M. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract. 2020;8(2):565-572.
McCamish M, Yoon W, McKay J. Biosimilars: biologics that meet patients' needs and healthcare economics. Am J Manag Care. 2016;22(13 Suppl):S439-S442.
Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
ICER. Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks. Institute for Clinical and Economical Review; September 24, 2018; 2018.
(GINA) GIfA. Difficult to treat & severe asthma in adolscents and adults: Diagnosis and management. V2.0 April 2019. https://ginasthma.org/severeasthma/. Accessed June 2020. 2019.
Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140(1):162-169.e2.
Health CAfDaTi. Clinical Review Report: Omalizumab (Xolair) Ottawa (ON); sep 2017; APPENDIX 5, Validity of Outcome Measures. Available from: https://www.ncbi.nlm.nih.gov/books/NBK533734
Vivot A, Boutron I, Beraud-Chaulet G, Zeitoun JD, Ravaud P, Porcher R. Evidence for treatment-by-biomarker interaction for FDA-approved oncology drugs with required pharmacogenomic biomarker testing. Sci Rep. 2017;7(1):6882.
Boire G, Allard-Chamard H. The 4-H of biomarkers in arthritis: a lot of help, occasional harm, some hype, Increasing Hope. J Rheumatol. 2019;46(7):758-763.
Agache I, Strasser DS, Pierlot GM, Farine H, Izuhara K, Akdis CA. Monitoring inflammatory heterogeneity with multiple biomarkers for multidimensional endotyping of asthma. J Allergy Clin Immunol. 2018;141(1):442-445.
Casale TB, Chipps BE, Rosén K, et al. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy 2018;73(2):490-497.
Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549-556.
Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
Muraro A, Dubois AEJ, DunnGalvin A, et al. Food allergy and anaphylaxis guidelines. Food allergy health-related quality of life measures. Allergy 2014;69(7):845-853.
Upton JEM, Poder TG, Begin P. Early introduction without screening is a good deal, if caregivers will buy it. Allergy 2019;74(2):213-215.
Jönsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357-359.
Akinbami LJ, Sullivan SD, Campbell JD, et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol. 2012;129(3 Suppl):S49-64.
Kim CH, Dilokthornsakul P, Campbell JD, van Boven JFM. Asthma cost-effectiveness analyses: are we using the recommended outcomes in estimating value? J Allergy Clin Immunol Pract. 2018;6(2):619-632.
Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis. 2005;20(3):193-200.
Langlois A, Lavergne M-H, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy Asthma Clin Immunol. 2020;16:25.
Goetghebeur M, Castro-Jaramillo H, Baltussen R, Daniels N. The art of priority setting. Lancet 2017;389(10087):2368-2369.
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Making. 2012;32(2):376-388.
Goetghebeur MM, Cellier MS. Can reflective multicriteria be the new paradigm for healthcare decision-making? The EVIDEM journey. Cost Eff Resour Alloc. 2018;16(Suppl 1):54.
Goetghebeur MM, Wagner M, Samaha D, et al. Exploring values of health technology assessment agencies using reflective multicriteria and rare disease case. Int J Technol Assess Health Care. 2017;33(4):504-520.
Goetghebeur MM, Wagner M, Khoury H, Rindress D, Gregoire JP, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients. Cost Eff Resour Alloc. 2010;8:4.
Institute for Healthcare I. The triple aim. Optimizing health, care and cost. Healthc Exec. 2009;24(1):64-66.
Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood). 2008;27(3):759-769.
Bégin P, Chan ES, Kim H, et al. CSACI guidelines for the ethical, evidence-based and patient-oriented clinical practice of oral immunotherapy in IgE-mediated food allergy. Allergy, Asthma & Clin Immunol. 2020;16(1):20.
Sabik LM, Lie RK. Priority setting in health care: lessons from the experiences of eight countries. Int J Equity Health. 2008;7:4.
Daniels N. Accountability for reasonableness. BMJ 2000;321(7272):1300-1301.